| Subject: | FDA Announces Updated Label with Boxed Warning for Entire Thiazolidinedione Class of Antidiabetic Drugs |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Tue, 14 Aug 2007 - 06:00 pm |
| The FDA has announced that after a review of postmarketing adverse event reports that an updated label with a boxed warning on the risks of heart failure was needed for the entire thiazolidinedione class of antidiabetic drugs. The drugs include:Avandia (rosiglitazone maleate) TabletsActos (pioglitazone hydrochloride) Tablets Avandaryl (rosiglitazone maleate and glimepiride) Tablets Avandamet (rosiglitazone maleate and metformin hydrochloride) Tablets Duetact (pioglitazone hydrochloride... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
External Links:
|
|
With over 20 years experience in regulatory compliance, MCN Healthcare brings you the most comprehensive regulatory compliance tool available. StayAlert! is the only comprehensive e-mail notification service available that not only notifies you of the changes in major federal regulations, but also provides the policies, procedures, tools and best practices to help you meet the changing regulation. StayAlert! actively monitors TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others so you don't have to. The StayAlert! system was designed by healthcare professionals actively working in the healthcare environment, who were faced with attempting to competently provide quality care and services while "doing more with less". StayAlert! provides the answer to efficiently performing a variety of required job components from one centralized virtual location. StayAlert! improves data sharing and communications, thus reducing cost, broadening access and providing a system of documentation and follow-up. |
|
